CAJ | 학술논문

目的：观察和比较局部晚期乳腺癌 FEC 序贯 T 方案序贯放疗与同步放疗的近期不良反应，评价同步放化疗模式治疗局部晚期乳腺癌的可行性。方法将83例 T3/T4期或 N2/N3期局部晚期乳腺浸润性导管癌改良根治术后的患者随机分为2组，序贯治疗组（41例）术后行 FEC 序贯 T 方案辅助化疗后行序贯放疗；同步治疗组（42例）在 FEC序贯 T 方案辅助化疗的多西他赛辅助化疗阶段即行同步放疗。观察两组患者的近期不良反应。结果83例患者均能完成治疗，后程同步治疗组辅助时间较同步治疗组平均缩短5.4周，无化疗中断病例。Ⅲ～Ⅳ级胃肠道反应及骨髓抑制的发生率无显著性差异（P>0.05）。结论局部晚期乳腺癌患者术后辅助同步放化疗能缩短治疗时间，对辅助化疗进程无明显影响，耐受性良好，值得进一步观察。
목적：관찰화비교국부만기유선암 FEC 서관 T 방안서관방료여동보방료적근기불량반응，평개동보방화료모식치료국부만기유선암적가행성。방법장83례 T3/T4기혹 N2/N3기국부만기유선침윤성도관암개량근치술후적환자수궤분위2조，서관치료조（41례）술후행 FEC 서관 T 방안보조화료후행서관방료；동보치료조（42례）재 FEC서관 T 방안보조화료적다서타새보조화료계단즉행동보방료。관찰량조환자적근기불량반응。결과83례환자균능완성치료，후정동보치료조보조시간교동보치료조평균축단5.4주，무화료중단병례。Ⅲ～Ⅳ급위장도반응급골수억제적발생솔무현저성차이（P>0.05）。결론국부만기유선암환자술후보조동보방화료능축단치료시간，대보조화료진정무명현영향，내수성량호，치득진일보관찰。
Objective To observe the toxicity of synchronous chemoradiotherapy and sequential schedule as adjuvant therapy after surgery for locally advanced breast cancer, and to evaluate the feasibility of synchronous chemoradiotherapy. Methods Eighty-three patients with prior breast surgery and histologically confirmed locally advanced cancer were included in this study. They received adjuvant chemotherapy FEC ( Fluorouracil, epirubicin and cyclophosphamide) followed by T (docetaxel). They were randomly divided into two groups and received synchronous chemoradiotherapy with docetaxel (42 cases) or sequential schedule (41 cases), respectively. Their clinical toxic reactions were assessed after all schedules. Results All patients finished all schedules. Compared with sequential group, the adjuvant therapy time in synchronous group reduced 5.4 weeks on average. The rates ofⅢ~Ⅳdegrees of gastrointestinal reactions or bone marrow had no significant difference (P>0.05). Conclusions Synchronous chemo-radiotherapy can shorten the treatment time for locally advanced breast cancer after surgery as an adjuvant therapy. It is a well-tolerated regimen, and had no effect on adjuvant chemotherapy process. Therefore, it is worth of further observation.